Therapeutic agent for sleep apnea
US5422374A · kind A · utility
8Cited by
4References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 1993 |
| Grant date | Jun 6, 1995 |
| Priority date | — |
| Expiry date | Mar 8, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Administration of ubidecarenone is effective for the therapy of sleep apnea. It is given at a dose of 1-3,000 mg per day in adults. It is especially effective to administer ubidecarenone to the patient before bed at a dose of 2-50 mg.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.